Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are regarded as a highly promising platform for the delivery of active pharmaceutical ingredients, particularly within the context of medical and pharmacological research. Conventional production techniques, such as nanoprecipitation, offer a reliable foundation for nanoparticle synthesis. However, they are associated with certain constraints, particularly in terms of particle size predictability, size distribution, and polydispersity index (PDI). These limitations present significant challenges in the context of medical applications, where precise control of particle size is essential to ensure the efficacy and safety of drug release.

In contrast, a novel microfluidic approach utilising the patented FDmiX system enables precise control of particle size through the employment of a uniquely engineered mixing chamber geometry. The geometry, which facilitates the formation of nanoparticles with the aid of a microfluidic nozzle, enables the production of particles with a size of 50 nm to 1 µm and ensures a narrow size distribution. By modulating the flow rates within the microfluidic channel, the particle size can be meticulously calibrated, thereby offering markedly enhanced predictability and reproducibility in comparison to the conventional nanoprecipitation approach, which frequently results in variable particle sizes and elevated PDI values. Furthermore, the microfluidic method produces a substantially lower PDI, resulting in a more uniform particle distribution and consistent drug release profiles. This enhanced quality control and process reliability, particularly relevant for pharmaceutical applications where particle size impacts pharmacokinetics and bioavailability, highlight the potential of the FDmiX microfluidic system as a superior alternative for the future of nanomedicine.